Dr. Ajay Verma currently serves General Partner at Formation Venture Engineering. His extensive clinical experience and insights are invaluable to helping guide life‑science platform technologies toward successful commercialization and exits.

Dr. Verma is a neurologist and pragmatic innovator devoted to the development of neurotherapeutics and neurodiagnostics. He has extensive direct hands-on experience in basic science discovery and invention, translation of promising science into clinical studies, biomarker development and validation, design and execution of experimental medicine and therapeutic clinical studies, and clinical care of patients with neurological disorders.

Prior to FVE, Dr. Verma was Executive Vice President and Head of Research & Development at Yumanity Therapeutics, overseeing R&D initiatives focused on developing drugs against novel targets for treating neurodegenerative diseases. He was also Executive Vice President of Research and Experimental Medicine at Codiak Biosciences. He also served as Chief Medical Officer at United Neuroscience where he led pipeline development, clinical strategy, and business development.
‍
Dr. Verma earned his Doctor of Medicine (M.D.) from Johns Hopkins University School of Medicine through a U.S. Army Health Professions Scholarship. He also completed a Doctor of Philosophy (Ph.D.) in Toxicology from Johns Hopkins Bloomberg School of Public Health.

Rahul is currently the Managing Partner and Co-Founder of Formation Venture Engineering. He is a seasoned entrepreneur and skilled investor across multiple sectors with over 14 years of experience in founding, scaling, and exiting innovative companies. He also serves on the boards of several cutting-edge companies such as Amprion, Akston Biosciences, LeviSense Medical, SAM.AI, and serves as a strategic advisor to Re-Nuble.

Rahul’s entrepreneurial journey also includes co-founding Ehsaas Organic, India’s first organic food home-delivery startup. There, he introduced fully automated hydroponic systems and led the company to profitability within six months. He was also the Co-Founder and Chief Revenue Officer at StrongArm Tech, where he played a critical role in turning the company into a leader in global industrial safety innovations. He helped secure strategic investment from 3M and drove adoption among major enterprise clients.

Rahul earned his Masters of Business Administration (MBA) from Stanford University Graduate School of Business and his Bachelor of Science (B.S.) in Biological Engineering from Massachusetts Institute of Technology.

Gary Magnant is Co-founder and General Partner at Formation Venture Engineering and Co-founder of FVE Foundry. He focuses on building new life science companies through repeatable venture design and early operational engagement.

His domain expertise spans translational innovation in therapeutics, diagnostics, and platform technologies, with a particular emphasis on neurology. He developed the Venture Engineering model to guide company creation through systematic milestone design and exit alignment.

Prior to Formation, Gary held senior roles across several biotech startups and venture-backed companies. He was previously Co-founder and CEO of Thrive Bioscience, Sage Science, and Owl Scientific (acquired by Thermo Fisher), and served as Vice President at MJ Research (now part of Bio-Rad). He also co-founded and served as President of ActivBiotics and ThermoCeramix, which went public in Canada. Gary holds numerous patents and inventions, has served on a wide range of bioscience-related boards, and was formerly Chairman and Trustee of Stoneridge Montessori School, where he received the Hallowell Award and has contributed to ≥$244 million in value creation, including $81.1 million in realized outcomes.

He holds an Master of Science (M.S.) in Microbiology from Montana State University and a Bachelor of Science (B.S.) in Biology from the University of Massachusetts Dartmouth.

W. Adam Hill is the Chief Technology Officer of Triple Sharp Venture Engineering, LLC. He is focused on positively impacting patients’ lives and bringing efficiency and effectiveness to discovering new medicines. Adam is a pioneer in the implementation of new technologies to effect greater efficiencies in life sciences.

Prior to joining Triple Sharp, Adam served as a long-time head of drug screening for Novartis, one of the top pharmaceutical companies in the world. In this role, Adam advanced new compounds into clinical development and evaluated new drug discovery technologies. He also served as a managing scientist at Millennium Pharmaceuticals and Schering-Plough. Adam received his D. Phil, Chemistry & Pharmacology, from the University of Oxford and conducted post-doctoral research at Harvard University and the University of Connecticut. 

Amanda Zimmerman is a Program Manager at Formation Venture Engineering, where she leads scientific and technical execution across early-stage life science companies. She manages complex R&D programs with a focus on operational clarity, cross-functional coordination, and milestone delivery.

Her domain expertise spans neuroscience, neuroengineering, and bioengineering. She brings deep technical experience in the design and implementation of research programs across biological and engineering disciplines, with a particular emphasis on translational science.

Before joining FVE, Amanda served as Director of Portfolio and Project Management at Axonis Therapeutics, where she planned and oversaw discovery, lead optimization, and preclinical work through IND-enabling studies on CNS-targeting small molecules. She led and collaborated with international consultants, internal scientists, and key stakeholders to define and execute program strategy. Previously, she was a Senior Scientist at the Christopher & Dana Reeve Foundation, where she engaged over 75 academic, business, and nonprofit stakeholders to assess the spinal cord injury research landscape and helped construct a chronic injury roadmap. She also authored a new manual for the Paralysis Resource Center, translating complex research into a community-friendly format.

Dr. Zimmerman earned her Doctor of Philosophy (Ph.D.) in Neuroscience from the Georgia Institute of Technology. She also completed a Bachelor of Science (B.S.) in Bioengineering at the University of Pittsburgh.